BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32651259)

  • 21. RNA N
    Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
    Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.
    Dong Z; Yeo KS; Lopez G; Zhang C; Dankert Eggum EN; Rokita JL; Ung CY; Levee TM; Her ZP; Howe CJ; Hou X; van Ree JH; Li S; He S; Tao T; Fritchie K; Torres-Mora J; Lehman JS; Meves A; Razidlo GL; Rathi KS; Weroha SJ; Look AT; van Deursen JM; Li H; Westendorf JJ; Maris JM; Zhu S
    Cancer Res; 2021 Jun; 81(11):2995-3007. PubMed ID: 33602789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of Aryl Hydrocarbon Receptor by Kynurenine Impairs Progression and Metastasis of Neuroblastoma.
    Wu PY; Yu IS; Lin YC; Chang YT; Chen CC; Lin KH; Tseng TH; Kargren M; Tai YL; Shen TL; Liu YL; Wang BJ; Chang CH; Chen WM; Juan HF; Huang SF; Chan YY; Liao YF; Hsu WM; Lee H
    Cancer Res; 2019 Nov; 79(21):5550-5562. PubMed ID: 31431462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
    Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
    Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
    Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
    J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma.
    Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY
    Mol Oncol; 2021 Apr; 15(4):1162-1179. PubMed ID: 33497018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface.
    Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM
    Cancer Res; 2019 Nov; 79(21):5652-5667. PubMed ID: 31501192
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
    Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.
    Chittavanich P; Saengwimol D; Roytrakul S; Rojanaporn D; Chaitankar V; Srimongkol A; Anurathapan U; Hongeng S; Kaewkhaw R
    Mol Oncol; 2024 Apr; 18(4):918-938. PubMed ID: 37975412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35.
    Liu PY; Tee AE; Milazzo G; Hannan KM; Maag J; Mondal S; Atmadibrata B; Bartonicek N; Peng H; Ho N; Mayoh C; Ciaccio R; Sun Y; Henderson MJ; Gao J; Everaert C; Hulme AJ; Wong M; Lan Q; Cheung BB; Shi L; Wang JY; Simon T; Fischer M; Zhang XD; Marshall GM; Norris MD; Haber M; Vandesompele J; Li J; Mestdagh P; Hannan RD; Dinger ME; Perini G; Liu T
    Nat Commun; 2019 Nov; 10(1):5026. PubMed ID: 31690716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
    Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
    Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
    Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
    J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.
    Samaraweera L; Spengler BA; Ross RA
    Oncol Rep; 2017 Jul; 38(1):545-550. PubMed ID: 28560387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.
    Zhang H; Liu T; Yi S; Gu L; Zhou M
    Mol Oncol; 2015 Aug; 9(7):1301-11. PubMed ID: 25864587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The KAT module of the SAGA complex maintains the oncogenic gene expression program in
    Malone CF; Mabe NW; Forman AB; Alexe G; Engel KL; Chen YC; Soeung M; Salhotra S; Basanthakumar A; Liu B; Dent SYR; Stegmaier K
    Sci Adv; 2024 May; 10(22):eadm9449. PubMed ID: 38820154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.